Martin Kolb

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

Luca Richeldi, Roland M. du Bois, Ganesh Raghu et al. · New England Journal of Medicine · 2014 · 4.6K citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +13

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases

Kevin R. Flaherty, Athol U. Wells, Vincent Cottin et al. · New England Journal of Medicine · 2019 · 2.3K citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacotherapy +11

Transient expression of IL-1β induces acute lung injury and chronic repair leading to pulmonary fibrosis

Martin Kolb, Peter J. Margetts, Daniel C. Anthony et al. · Journal of Clinical Investigation · 2001 · 741 citations · Full text

Veterinary Medicine, Pathobiology, Pathology +17

Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals

David J. Lederer, Scott C. Bell, Richard D. Branson et al. · Annals of the American Thoracic Society · 2018 · 722 citations · Full text

Public Health, Biostatistics, Causal Inference +16

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 559 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +12